NovoCure Limited (NVCR)
NASDAQ: NVCR · Real-Time Price · USD
12.06
+0.05 (0.42%)
Mar 13, 2026, 4:00 PM EDT - Market closed
NovoCure Stock Forecast
Stock Price Forecast
The 6 analysts that cover NovoCure stock have a consensus rating of "Buy" and an average price target of $28.08, which forecasts a 132.84% increase in the stock price over the next year. The lowest target is $14.5 and the highest is $49.
Price Target: $28.08 (+132.84%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for NovoCure stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Hold | 3 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $47 → $49 | Strong Buy | Maintains | $47 → $49 | +306.30% | Feb 26, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $39 → $47 | Strong Buy | Maintains | $39 → $47 | +289.72% | Feb 12, 2026 |
| Wedbush | Wedbush | Hold Reiterates $18 | Hold | Reiterates | $18 | +49.25% | Jan 15, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $42 → $39 | Strong Buy | Maintains | $42 → $39 | +223.38% | Jan 13, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $38 → $42 | Strong Buy | Maintains | $38 → $42 | +248.26% | Oct 30, 2025 |
Financial Forecast
Revenue This Year
705.96M
from 655.35M
Increased by 7.72%
Revenue Next Year
753.51M
from 705.96M
Increased by 6.74%
EPS This Year
-1.60
from -1.22
EPS Next Year
-1.28
from -1.60
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 732.5M | 823.2M | |||
| Avg | 706.0M | 753.5M | |||
| Low | 672.2M | 683.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 11.8% | 16.6% | |||
| Avg | 7.7% | 6.7% | |||
| Low | 2.6% | -3.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -1.39 | -1.17 | |||
| Avg | -1.60 | -1.28 | |||
| Low | -1.82 | -1.39 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.